Warning Signs of a Meningioma
Meningiomas are slow-growing tumors, and symptoms may develop over months or years. The most common symptoms include: persistent headaches that worsen over time (experienced by the majority of patients), vision problems (blurred vision, double vision, partial vision loss), seizures (occurring in over one-third of patients), hearing loss or ringing in the ears (tinnitus), and weakness or numbness in the arms or legs.
Symptoms by Tumor Location
Symptoms vary depending on where the meningioma develops. Convexity meningiomas (top of brain) cause seizures and focal weakness. Parasagittal meningiomas cause leg weakness and seizures. Sphenoid wing meningiomas cause visual problems and facial pain. Posterior fossa meningiomas cause balance problems and hearing loss. Olfactory groove meningiomas cause loss of smell.
When to Seek Imaging
If you received Depo-Provera injections and experience new or worsening headaches, any visual changes, a seizure, unexplained weakness or numbness, or cognitive changes, request a contrast-enhanced MRI of the brain from your healthcare provider. Early detection improves treatment outcomes and strengthens your legal claim.
Documenting Your Symptoms
For both medical and legal purposes, keep a detailed symptom diary recording: when symptoms started, frequency and severity, how symptoms affect daily activities, all medical appointments and imaging results, and timeline of Depo-Provera use. This documentation is critical evidence in your case.
Scientific Evidence
Medroxyprogesterone Acetate and Meningioma: A Global Issue
Roland N, Froelich S, Weill A (2025). Frontiers in Global Womens Health
View on PubMed→Use of High-Dose Medroxyprogesterone Acetate and Risk of Intracranial Meningioma
Roland N, Neumann A, Hoisnard L, Gagne JJ, Froelich S, Weill A (2024). The BMJ
View on PubMed→The Association between Medroxyprogesterone Acetate Exposure and Meningioma
Griffin BR et al. (2024). Cancers
View on PubMed→Frequently Asked Questions
Related Pages
Depo-Provera Meningioma Brain Tumor
Meningioma — a tumor in the tissue surrounding the brain — is the primary injury in Depo-Provera lawsuits. Studies show long-term users face up to a 5.6x increased risk. The tumor can cause seizures, vision loss, and require major brain surgery.
Depo-Provera Long-Term Use Risks
Long-term Depo-Provera use carries multiple serious risks: meningioma brain tumors (up to 5.6x risk), significant bone density loss (black box warning), weight gain, depression, and delayed return to fertility. The FDA recommends limiting use to 2 years.
Depo-Provera Settlement Amounts
No Depo-Provera meningioma cases have settled or gone to trial yet. Projected settlements based on comparable pharmaceutical brain injury litigation suggest $75,000 to $1.5 million+ depending on injury severity.
Pfizer Depo-Provera Lawsuit
Pfizer inherited Depo-Provera when it acquired Pharmacia & Upjohn in 2002. Despite international warnings dating to 2015, Pfizer did not add a U.S. meningioma warning until December 2025. Plaintiffs allege a pattern of delayed safety action prioritizing revenue over patient safety.
Depo-Provera Alternatives After Diagnosis
If you are diagnosed with a meningioma, the FDA recommends discontinuing Depo-Provera immediately. Safer contraceptive alternatives exist that do not carry meningioma risk, including copper IUDs, barrier methods, and non-progestin options.
Depo-Provera Military Veterans
Military women were disproportionately prescribed Depo-Provera due to its convenience for deployment. If you received Depo-Provera during military service and were later diagnosed with a meningioma, you may be eligible for both civil lawsuit compensation and VA benefits.
Depo-Provera MRI Screening
Current guidelines do not recommend routine MRI screening for asymptomatic Depo-Provera users. However, the updated FDA label instructs providers to monitor for meningioma symptoms. If you have symptoms, request brain imaging immediately.
Depo-Provera Brain Tumor Lawsuits Lawsuit
Depo-Provera (medroxyprogesterone acetate / MPA) is a contraceptive injection administered every three months. Over 2,000 lawsuits consolidated in MDL 3140 in the Northern District of Florida allege that Pfizer failed to warn about a significantly elevated risk of meningioma — a tumor in the tissue surrounding the brain and spinal cord. Women who received the shot for more than one year face up to a 5.6-fold increased risk, and the risk escalates with duration of use.
View full case overview